| 0.711 -0.089 (-11.11%) | 08-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.22  |
1-year : | 1.47 |
| Resists | First : | 1.04 |
Second : | 1.25 |
| Pivot price | 0.9 |
|||
| Supports | First : | 0.7 |
Second : | 0.58 |
| MAs | MA(5) : | 0.82 |
MA(20) : | 0.93 |
| MA(100) : | 1.21 |
MA(250) : | 1.84 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 10.3 |
| RSI | RSI(14): 27.7 |
|||
| 52-week | High : | 3.4 | Low : | 0.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABVC ] has closed below the lower bollinger band by 9.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ABVC ] is to continue within current trading range. Bollinger Bands are 35.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.84 - 0.84 | 0.84 - 0.85 |
| Low: | 0.69 - 0.69 | 0.69 - 0.7 |
| Close: | 0.7 - 0.72 | 0.72 - 0.72 |
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Tue, 25 Aug 2026
ABVC BioPharma (NASDAQ: ABVC) puts 6.6M-share land deal to a shareholder vote - Stock Titan
Wed, 12 Aug 2026
ABVC BIOPHARMA, INC. Q2 2026: Revenue $0 EPS $(0.03) — 10-Q Summary - TradingView
Mon, 27 Jul 2026
ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 18.1 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 442 (K) |
| Shares Short P.Month | 367 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -69.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -2.46 |
| PEG Ratio | 0 |
| Price to Book value | 1.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|